%PDF-1.6
%
1 0 obj
<>
endobj
2 0 obj
<>stream
2013-07-19T19:36:34+03:00
2013-07-19T19:36:34+03:00
2013-07-19T19:36:34+03:00
application/pdf
bs-0012M-PE-Cy7
uuid:b0154c9d-652c-4f3a-be3c-f28f08c8cd06
uuid:6182dce9-7c23-4bf1-bf6e-006177941638
Acrobat Web Capture 9.0
endstream
endobj
5 0 obj
<>
endobj
6 0 obj
<>
endobj
3 0 obj
<>
endobj
7 0 obj
<>
endobj
11 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text/ImageC/ImageI]/XObject<>>>/Type/Page>>
endobj
12 0 obj
[34 0 R]
endobj
13 0 obj
<>stream
/CS0 cs 1 scn
10 815.443 574.5 -732.504 re
f
BT
0.2 scn
/TT0 1 Tf
6.6111 0 0 6.6111 21.2388 767.1818 Tm
(www.biossusa.com)Tj
0 -1.5 TD
(support@biossusa.com)Tj
-0.012 Tw T*
[(800.501.7654)-34( )1([DOMESTIC])]TJ
0 -1.5 TD
[(+1.781.569.5821)-57( )1([INTERNATIONAL])]TJ
ET
q
/GS0 gs
140.8153076 0 0 -79.3325653 443.6847076 810.153656 cm
/Im0 Do
Q
BT
0 scn
/TT1 1 Tf
0 Tw 9.2555 0 0 9.2555 21.2388 715.6157 Tm
[(bs)-67(-)-69(0012M)-59(-)-69(PE)-14(-)-69(Cy7)]TJ
/TT0 1 Tf
-0.04 Tw 7.2722 0 0 7.2722 28.5109 669.3383 Tm
[(Conjugated)-58( Primary)-1( Antibodies)]TJ
/TT1 1 Tf
0 Tw 0 -2.091 TD
(Background:)Tj
/TT0 1 Tf
-0.04 Tw 0 -1.455 TD
[(The)-59( synucleins,)-6( including)-72( alpha)-65(-)-1(synuclein)-28( \(also)-56( designated)-15( NACP)-35( for)-52( nonamyloid)-15( component)-84( precursor\),beta)-27(-)]TJ
0 -1.455 TD
[(synuclein)-28( \(also)-56( designated)-15( PNP)-49( 14)-90( for)-52( phospho)-64(-)-1(neuroprotein)-79( 14\)and)-71( gamma)-81(-)-1(synuclein)-28( \(also)-56( designated)-15( persyn)]TJ
0 -1.455 TD
[(or)-6( BCSG1)-40( for)-52( breast)-74( cancer)-18(-)-1(specific)-50( gene)-19( 1\)are)-24( presynaptic)-48( protein)-79( abundant)-18( in)-31( neurons.)-57( alpha)-64(-)-1(synuclein,)-89( a)]TJ
T*
[(component)-84( of)-48( Alzheimer\222s)-31( disease)-22( amyloid)-37( plaques,)-34( is)-52( localized)-79( to)-32( neuronal)-52( cell)-9( bodies)-59( and synapses.)-63( Coordinate)]TJ
0 -1.455 TD
[(expression)-45( of)-48( alpha)-65(-)-1(synucleinand)-28( beta)-62(-)-1(synuclein)-28( may)-46( be)-12( important)-88( during)-7( hematopoetic)-28( cell)-10( differentiation.)-11( In)]TJ
T*
[(patients)-40( with)-46( Parkinson\222s)-75( disease,)-82( a)-20( mutant)-33( form)-30( of)-48( alpha)-65(-)-1(synuclein)-28( has)-16( been)-19( found)-15( and gamma)-81(-)-1(synuclein)-28( is)]TJ
0 -1.455 TD
[(associated)-48( with)-46( axonal)-34( pathology.)]TJ
/TT1 1 Tf
0 Tw 0 -1.909 TD
(Purification:)Tj
/TT0 1 Tf
-0.04 Tw 6.727 -0.091 Td
[(Was)-36( purified)-38( by)-40( Protein)-81( A)-36( and peptide)-90( affinity)-82( chromatography.)]TJ
/TT1 1 Tf
0 Tw -6.727 -2 Td
(Storage:)Tj
/TT0 1 Tf
-0.04 Tw 0 -1.455 TD
[(Prepared)-46( as)-29( lyophilized)-45( powder)-87( or)-6( liquid)-13( and shipped)-37( on)-81( ice.)-26( Store)-44( at)-50( -)-1(20\260C)-18( for)-52( one)-9( year.)-61( Protect)-73( from)-30( light.)]TJ
/TT1 1 Tf
0 Tw 0 -1.909 TD
(Reconstitution:)Tj
/TT0 1 Tf
-0.04 Tw 0 -1.455 TD
[(If)-36( the)-36( antibody)-25( is)-52( in)-31( liquid)-13( form,)-91( no)-81( reconstitution)-78( needed.)]TJ
0 -2.909 TD
[(Reconstitution)-90( is)-52( only)-81( required)-62( for)-52( the)-36( lyophilized)-45( antibody.)-86( Please)-15( refer)-92( to)-32( the)-37( reconstitution)-78( instruction)-26( card)-10( in)]TJ
0 -1.455 TD
[(the)-36( package.)]TJ
/TT1 1 Tf
0 Tw 54.182 28.364 Td
(Size:)Tj
/TT0 1 Tf
-0.04 Tw 3 -0.091 Td
[(100ul)-29( or)-6( 100ug)-69( lyophilized)]TJ
/TT1 1 Tf
0 Tw -3 -2.818 Td
(Concentration:)Tj
/TT0 1 Tf
8.091 -0.091 Td
(1ug/uL)Tj
/TT1 1 Tf
-8.091 -2.818 Td
(Host:)Tj
/TT0 1 Tf
3.273 -0.091 Td
(Mouse)Tj
/TT1 1 Tf
-3.273 -1.909 Td
(Reactivities:)Tj
0.2 scn
/TT0 1 Tf
6.6111 0 0 6.6111 422.5294 623.7221 Tm
(Human,Mouse,Rat,Dog,Pig,Cow,Horse,Sheep,Guinea)Tj
0 -1.5 TD
(Pig,)Tj
0 scn
/TT1 1 Tf
7.2722 0 0 7.2722 422.5294 599.9224 Tm
(Application:)Tj
ET
q
10 36 575 780 re
W n
q 1 0 0 1 432.4459 582.4031 cm
0 0 m
0 1.322 -1.983 1.322 -1.983 0 c
-1.983 -1.322 0 -1.322 0 0 c
f
Q
Q
BT
/TT0 1 Tf
7.2722 0 0 7.2722 439.057 580.7503 Tm
[(IF\(1:100)-3(-)-1(500\))]TJ
ET
q
10 36 575 780 re
W n
q 1 0 0 1 432.4459 571.8254 cm
0 0 m
0 1.322 -1.983 1.322 -1.983 0 c
-1.983 -1.322 0 -1.322 0 0 c
f
Q
Q
BT
/TT0 1 Tf
-0.04 Tw 7.2722 0 0 7.2722 439.057 570.1726 Tm
[(Not)-1( yet)-6( tested)-8( in)-31( other)-43( applications.)]TJ
0 -1.455 TD
[(Optimal)-36( working)-62( dilutions)-48( must)-4( be)]TJ
0 -1.455 TD
[(determined)-86( by)-40( the)-36( end)-90( user.)]TJ
/TT1 1 Tf
-0.02 Tw -2.273 -3.818 Td
[(Antibody)-48( Type:)]TJ
/TT0 1 Tf
0 Tw 8.182 -0.091 Td
(Polyclonal)Tj
/TT1 1 Tf
-8.182 -1.909 Td
(Isotype:)Tj
0.2 scn
/TT0 1 Tf
6.6111 0 0 6.6111 465.5012 506.7066 Tm
(IgG)Tj
0 scn
/TT1 1 Tf
-0.02 Tw 7.2722 0 0 7.2722 422.5294 492.8234 Tm
[(Molecular)-1( Weight:)]TJ
0.2 scn
/TT0 1 Tf
0 Tw 6.6111 0 0 6.6111 501.2008 492.8234 Tm
(15kDa)Tj
0 scn
/TT1 1 Tf
7.2722 0 0 7.2722 422.5294 478.9402 Tm
(Preservatives:)Tj
0.2 scn
/TT0 1 Tf
-0.012 Tw 6.6111 0 0 6.6111 486.6565 478.9402 Tm
[(10ug/uL)-59( )1(BSA)-54( )1(and)-64( )1(0.1%)-28( )1(NaN3.)]TJ
0 scn
0.021 Tw 5.9499 0 0 5.9499 422.5294 451.8349 Tm
[(For)-20( )1(research)-16( )1(use)-26( )1(only.)-91( )1(CAUTION:)-12( )1(Not)-11( )1(for)-1( )1(human)-72( )1(or)]TJ
0 -1.333 TD
[(animal)-94( )1(therapeutic)-36( )1(or)-97( )1(diagnostic)-13( )1(use.)]TJ
ET
q
/GS0 gs
561.9390106 0 0 -0.6611023 18.5943604 707.0213165 cm
/Im1 Do
Q
BT
/TT0 1 Tf
0 Tw 10.5777 0 0 10.5777 21.2388 84.9218 Tm
( )Tj
ET
q
10 36 575 780 re
W n
/CS3 cs 0.302 0.306 0.333 scn
q 1 0 0 1 19.2555 691.8159 cm
0 0 m
0 1.763 -2.644 1.763 -2.644 0 c
-2.644 -1.763 0 -1.763 0 0 c
f
Q
Q
BT
/CS3 cs 0.302 0.306 0.333 scn
/C2_0 1 Tf
9.2555 0 0 9.2555 28.5109 689.1715 Tm
[<00300052005800560048>-27<0003>7<002400510057004C>-28<0010>-69<012E>-14<0010>-69<0036005C005100580046004F0048004C0051>-3<0003>7<00330052004F005C0046004F005200510044004F>-4<0003>7<002400510057004C004500520047005C000F>-47<0003>7<00330028>-14<0010>-69<0026005C001A>-49<0003>7<004600520051004D0058004A0044005700480047>]TJ
ET
q
/GS0 gs
99.1657104 0 0 -74.704834 25.2054138 396.9631805 cm
/Im2 Do
Q
BT
/CS0 cs 0 scn
/TT0 1 Tf
10.5777 0 0 10.5777 25.2054 313.0029 Tm
( )Tj
ET
q
/GS0 gs
99.1657104 0 0 -74.704834 152.7986298 396.9631805 cm
/Im3 Do
Q
BT
/TT0 1 Tf
10.5777 0 0 10.5777 152.7986 313.0029 Tm
( )Tj
ET
q
/GS0 gs
99.1657104 0 0 -74.704834 281.052948 396.9631805 cm
/Im4 Do
Q
BT
/TT0 1 Tf
10.5777 0 0 10.5777 281.0529 313.0029 Tm
( )Tj
-24.187 -2.25 Td
( )Tj
12.063 0 Td
( )Tj
12.125 0 Td
( )Tj
-24.187 -2.25 Td
( )Tj
12.063 0 Td
( )Tj
12.125 0 Td
( )Tj
-0.04 Tw 7.2722 0 0 7.2722 26.5276 233.6703 Tm
[(For)-30( full)-30( size)-82( images)-63( and description)-26( please)-13( click)-31( )]TJ
/CS3 cs 0 0.6 0.8 scn
0 Tw 6.6111 0 0 6.6111 179.9039 233.6703 Tm
(HERE)Tj
/CS0 cs 0 scn
7.2722 0 0 7.2722 196.4315 233.6703 Tm
(.)Tj
ET
q
/GS0 gs
0.6611023 0 0 -594.9942474 408.6461639 706.3601837 cm
/Im5 Do
Q
q
/GS0 gs
5.9499359 0 0 -40.3273926 578.5500793 123.2658234 cm
/Im6 Do
Q
endstream
endobj
14 0 obj
<>
endobj
15 0 obj
(*zxlD6)
endobj
27 0 obj
<>stream
Hy\E323#3
P̴,HLEK"+E+2VTD%EH# }wfwfvvc_3?{feޝ@HHHHHH*豘V]
zן)@-9.q2BÇEڂ8g "2vn>u2]/Yz \S@ 7.M&p?o9v 0'rKś-;(Au.J%% %&˶0>6`TxOzzo(VDY*AZp ËgAs^.㮌+2Ȱ$E['FC:OMCIVVDD3}`u߈buߨɴ4қԭV^V0XF ϓ@i|Y|.?i'3}Ŵ+ޘaa:
3g},F"kNɳՕx57,H)X7*v/Mո+(fWr=WӃJcߓtG16sPt:t"9G
if
3do\ˢ|c:1&<ЭWnPdq0IRgu~惘n9BWV2T6~}rs4h-D.sgV/n3;q@hThI*jTJqJK2c!QT7;60
5NoJݻ'rBP%ȍ4
P(/CJC1
9eڴ}5S{"wty@P5e*Zg~?S(Sɗ,ʽv 2[̋t_Z\d&}/2YϹO&y#
?P>,0P-
asds[U꼩\=T~)S>B,gk$7+j0?60<&uźg
A]_@en%Mȝ~5PSu$^2s0RSPw L9٦n9$vڣ=f#g 7,Oa
:ܾ.4+H!=MvF(G|YU
ITR)>@✧*[j5KoB{Kp,`姙$JO궒jvż@r3`w\A%jSx+>m;5ا@._1:T#q]wrTC8r:lU4P}~Y]XwJ~b:YQϗLP-X_ֻа2$ݥC=~P]VҘLhu?S'\C:7"4dD*%9 Ogfe\OLoTy5Qkj.84,: t:_YON3˃:O/r犁3t!Psbty{aETu7nMѶ f+^Y6zHic?R%+C,γL =ZJ1H+,x^
I!u2{5x_@LI6[w5LN5:xXoEgf9tu=yùw=aґza*҃K`驪eP/y*sσn3N{ME\8g: *fz#W??L